TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing

Telo Genomics advances multi-center MRD assay validation, targeting commercialization by end-2027.

What the company is saying

Telo Genomics is emphasizing the expansion and validation of its TELO-MRD liquid-biopsy assay for measurable residual disease in multiple myeloma, positioning it as a competitor to Adaptive Biotechnologies' clonoSEQ. The narrative centers on a multi-center, international clinical research program with cohorts in France, Greece, Canada, and the United States, aiming to build a robust comparative dataset. The company highlights the proprietary TeloView® platform and stresses the scientific credibility of its approach, referencing over 190 peer-reviewed publications and more than 30 clinical studies involving over 3,000 patients. CEO and Chairman John Farlinger is quoted to reinforce the company’s confidence in the assay’s potential clinical utility and the strategic importance of expanding beyond a single cohort. The announcement is framed as a step toward commercialization, with a stated goal of launching TELO-MRD by the end of 2027. The company is clear that TELO-MRD is not yet commercially available and that these studies are for research purposes only, with results requiring further confirmation.

What the data suggests

The company has secured or is in the process of securing clinical samples from several international sites: approximately 25–30 samples from the University of Athens, 10 additional MRD monitoring time points from Jewish General Hospital in Montreal, and ongoing recruitment at Cleveland Clinic in the United States. Comparative testing on the IFM 2018-04 cohort from the University of Nantes is scheduled to begin in Q4 2026, providing a direct head-to-head comparison with clonoSEQ. The company’s technology has been used in over 30 clinical studies and validated in more than 3,000 patients, but no new clinical performance metrics or head-to-head results are disclosed in this update. The evidence base is broad but historical; the current announcement is about study setup and sample acquisition, not clinical outcomes. Commercialization is explicitly targeted for the end of 2027, but no regulatory, reimbursement, or commercial partnership milestones are reported. The data supports incremental operational progress but does not yet demonstrate clinical superiority or readiness for market launch.

Analysis

The announcement is upbeat and details concrete steps in ongoing clinical validation, including specific sample numbers and study sites, which grounds the narrative in measurable progress. However, the majority of key claims are forward-looking, focusing on intended outcomes (statistical robustness, reproducibility, and eventual commercialization by end-2027) rather than realised results. The most significant milestone—comparative testing on the French cohort—will not begin until Q4 2026, and commercial launch is not expected until late 2027, making the execution distance long-term. While the company references a substantial body of peer-reviewed validation, the current update is about research progress, not clinical or commercial endpoints. There is no mention of large capital outlays or immediate financial impact, so the capital intensity flag is false. The tone is moderately promotional, emphasizing future potential and broad validation, but the evidence supports only incremental research progress at this stage.

Risk flags

• ●Execution risk is significant, as the company must coordinate multi-center studies across France, Greece, Canada, and the United States, each with its own logistical and regulatory hurdles. Delays in sample acquisition, data harmonization, or study initiation could push back key milestones.
• ●Clinical validation risk is high because the TELO-MRD assay’s comparative performance against clonoSEQ is not yet demonstrated; if results do not show clear advantages or parity, commercial prospects could be limited.
• ●Commercialization risk is present, as the company targets a market launch by end-2027 but has not disclosed regulatory submission plans, reimbursement strategies, or commercial partnerships, all of which are critical for adoption in the competitive MRD testing market.
• ●Financial risk is implicit, as the announcement does not address funding requirements or cash runway for sustaining multi-year, multi-center clinical research and development activities. Extended timelines could increase capital needs.

Bottom line

Telo Genomics is making steady operational progress toward validating its TELO-MRD assay for multiple myeloma, with active studies in France, Greece, Canada, and the U.S. and a commercialization goal set for the end of 2027. The company’s technology has historical validation in over 3,000 patients and 30+ studies, but this update contains no new clinical performance data or regulatory milestones. The next major catalyst—comparative testing on the French cohort—will not start until Q4 2026, leaving a long execution runway and considerable risk before commercial value can be realized. Investors should watch for concrete clinical results and regulatory progress as the key inflection points. The most important takeaway is that while the company is building a foundation for future value, the path to commercialization remains long and unproven.

Announcement summary

(TSXV:TELO) (OTCQB:TDSGF) Telo Genomics Corp. announced it is advancing multiple clinical research initiatives to expand the comparative evaluation of its blood-based TELO-MRD assay against Adaptive Biotechnologies' clonoSEQ assay, an NGS-based method for measurable residual disease (MRD) assessment in multiple myeloma. TELO-MRD is a liquid-biopsy approach that combines enumeration of circulating myeloma plasma cells with three-dimensional telomere profiling using the proprietary TeloView® platform, designed to detect residual disease in peripheral blood and assess genomic instability. The company is pursuing a multi-center strategy to obtain a broad and diverse collection of clinical samples with available NGS-MRD results to support continued validation of TELO-MRD. Telo Genomics previously disclosed expected receipt of clinical samples from the IFM 2018-04 study by the University of Nantes, France, for which Adaptive clonoSEQ MRD results have already been collected; comparative testing on that cohort is scheduled to commence during the calendar fourth quarter 2026. The company is also advancing additional studies involving Greek, U.S., and Canadian cohorts to augment the planned French study with Johnson & Johnson. At the University of Athens, Greece, Telo Genomics is obtaining an additional cohort of approximately 25-30 clinical samples with available Adaptive clonoSEQ MRD data. At Jewish General Hospital, Montreal, Canada, the company has identified 10 additional MRD monitoring time points from its ongoing collaborative study, subject to the availability of corresponding NGS results. In collaboration with Dr. Sandra Mazzoni at Cleveland Clinic, United States, the company is actively recruiting patients with existing Adaptive clonoSEQ results to support additional comparative testing. These multi-center initiatives are intended to increase overall sample size, strengthen statistical robustness, and assess reproducibility of TELO-MRD performance across diverse clinical populations. Pursuing these studies in parallel is expected to accelerate the generation of comparative clinical evidence while preparations for the French study continue. John Farlinger, Chief Executive Officer and Chairman of Telo Genomics, stated that expanding beyond a single cohort will allow evaluation of performance across independent patient populations and strengthen evidence supporting potential clinical utility as the company moves toward commercialization, which is planned for 2027. TELO-MRD is not yet commercially available, and the company intends to continue development with the objective of a commercial application by the end of calendar 2027. These studies are research comparisons and are not a basis for treatment decisions; results will require confirmation in larger, independent studies. The company's proprietary technology has been substantiated in over 190 peer-reviewed publications and in more than 30 clinical studies involving over 3,000 patients with multiple cancers and Alzheimer's disease. The lead application, Telo-MM, is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma.

Disagree with this article?